Skip to main
TIL

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio Inc. is focusing on the development of a promising cell therapy pipeline centered around its autologous tumor infiltrating lymphocyte (TIL) therapies and the innovative Co-Stimulatory Antigen Receptor (CoStAR) platform, which has the potential to significantly enhance cancer treatment options. The company's lead product candidate, ITIL-306, is designed to target a tumor-associated antigen found in multiple solid tumors, indicating a broad applicability that could drive substantial market interest and uptake. Additionally, the positive outcomes from related clinical developments in the bispecific class suggest that advancements in the TIL sector may capitalize on a favorable market environment, potentially contributing to Instil Bio's growth trajectory.

Bears say

Instil Bio Inc. is currently facing a negative outlook due to a lack of convincing clinical trial results, as indicated by bearish investor concerns regarding the similarity of overall survival (OS) curves that suggest minimal improvement in patient outcomes. Furthermore, the company is exposed to significant operational risks, including potential delays in the clinical development of their therapy candidates and the possibility of not producing favorable clinical data for key products such as AXN-2510 targeting non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC). Lastly, the potential for medium- to long-term dilution risks poses an additional threat to shareholder value, compounding the overall apprehension surrounding the stock.

Instil Bio (TIL) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Instil Bio (TIL) has a Strong Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.